New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 8, 2012
04:55 EDTDXCM, DXCM, DXCM, SNY, SNY, SNY, MDT, MDT, MDT, RHHBY, RHHBY, RHHBY, BAYRY, BAYRY, BAYRYDiabetes Technology Society to host a meeting
12th Annual Diabetes Technology Society Meeting is being held in Bethesda, Maryland on November 8-10.
News For DXCM;SNY;MDT;RHHBY;BAYRY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 17, 2015
14:59 EDTSNYL'Oreal CEO 'ready' to sell Sanofi stake if needed, Barron's says
Subscribe for More Information
May 15, 2015
13:33 EDTMDTMedtronic: TYRX antibacterial envelope reduces cardiac device infection rates
Subscribe for More Information
10:29 EDTSNY, BAYRYAmerican Urological Association to hold an annual meeting
Subscribe for More Information
09:31 EDTBAYRYAmerican Thoracic Society to hold a conference
ATS 2015 Conference is being held in Denver on May 15-20.
08:12 EDTMDTMedtronic Micra TPS meets initial safety, performance measures
Subscribe for More Information
07:26 EDTBAYRYBayer expecting crops and seeds industry consolidation, Reuters reports
Subscribe for More Information
May 14, 2015
14:54 EDTBAYRYJohnson & Johnson unit reports results of VENTURE-AF trial
Subscribe for More Information
13:34 EDTMDTMedtronic: Micra transcatheter pacemaker meets initial safety measures in study
Subscribe for More Information
13:31 EDTMDTMedtronic says Evera MRI ICD study meets safety, efficacy endpoints
Subscribe for More Information
09:41 EDTMDTLeerink medical devices analyst holds a cardiology luncheon meeting
Subscribe for More Information
09:22 EDTRHHBYLeerink pharma/biotech analysts hold an analyst/industry conference call
Subscribe for More Information
May 13, 2015
18:43 EDTBAYRYBayer to present Xofigo, ODM-201 data at 2015 ASCO meeting
Subscribe for More Information
18:12 EDTRHHBYGenentech alectinib shrank tumors in about half of ALK-positive NSCLC patients
Subscribe for More Information
17:04 EDTRHHBYGenentech announces interim results from POPLAR study
Genentech, a member of the Roche Group announced interim results from a global, randomized Phase II study, POPLAR, in people with previously treated non-small cell lung cancer, NSCLC. The study showed the investigational cancer immunotherapy MPDL3280A doubled the likelihood of survival; hazard ratio [HR]=0.47) in people whose cancer expressed the highest levels of PD-L1 compared with docetaxel chemotherapy. An improvement in survival was also observed in people who had medium and high or any level of PD-L1 expression, as characterized by a test being developed by Roche. MPDL3280A was generally well tolerated and adverse events were consistent with what has been previously reported for MPDL3280A in NSCLC. Updated results will be presented in an oral session at the 51st Annual Meeting of the American Society of Clinical Oncology. “In our study of MPDL3280A in previously treated lung cancer, the amount of PD-L1 expressed by a person’s cancer correlated with improvement in survival,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development. “The goal of PD-L1 as a biomarker is to identify people most likely to experience improved overall survival with MPDL3280A alone, and which people may be appropriate candidates for a combination of medicines.”
07:31 EDTSNYHeart Rhythm Society to hold a conference
Heart Rhythm 2015 is being held in Boston on May 13-16.
07:05 EDTSNYSanofi exercises option on therapeutic program with Selecta Biosciences
Selecta Biosciences., a clinical stage biotechnology company developing a novel class of targeted antigen-specific immune therapies, today announced that, under the terms of an existing strategic global collaboration, Sanofi has exercised its option to an exclusive license to develop an immunotherapy for the treatment of celiac disease. Under the terms of the collaboration, Selecta is eligible to receive research support and several pre-clinical, clinical, regulatory and sales milestones totaling up to $300 million for this new program in celiac disease. Additionally, Selecta is also entitled to up to double digit tiered royalties as percentage of product net sales for any commercialized immunotherapy resulting from these efforts with Sanofi. November 2012, Selecta announced that they had formed a strategic global collaboration to discover highly targeted, antigen-specific immunotherapies for life threatening allergies. Under the agreement, Sanofi obtained a first exclusive license to develop an immunotherapy designed to abate acute immune responses against a life threatening food allergen and an option to develop two additional candidate immunotherapies for allergies and celiac disease. With the exercise of this option by Sanofi, Selecta and Sanofi now have two initiatives actively advancing immune tolerance treatments under the terms of the 2012 agreement. In October 2014, Selecta and JDRF announced another collaboration with Sanofi to research novel antigen-specific immune therapies for Type 1 Diabetes.
May 12, 2015
10:02 EDTMDTMedtronic receives FDA approval and CE Mark for Advance ST cryoballoon
Subscribe for More Information
May 11, 2015
05:11 EDTRHHBYRoche receives FDA approval for cobas KRAS Mutation Test
Roche announced that the FDA has approved the cobas KRAS Mutation Test for diagnostic use. The real-time PCR test is designed to identify KRAS mutations in tumor samples from metastatic colorectal cancer, or mCRC, patients and aid clinicians in determining a therapeutic path for them.
May 8, 2015
17:22 EDTBAYRYBayer sends letter to NY Times regarding Essure story
Subscribe for More Information
14:11 EDTBAYRYFDA approves Bayer plague treaatment Avelox
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use